Fabino Life Sciences Ltd.

26.75 -1.05 ▼-3.8%

05 December 2023, 09:19:00 AM
Volume: 3,000

Company Profile

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.fabinolife.com
Market Cap 5.84 Cr.
Enterprise Value(EV) 6.32 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 0.05 Trailing Twelve Months Ending 2023-03
Price-Earning Ratio (PE) 540.56 Trailing Twelve Months Ending 2023-03
Industry PE 38.73 Trailing Twelve Months Ending 2023-03
Book Value / Share 19.59 Trailing Twelve Months Ending 2023-03
Price to Book Value 1.42 Calculated using Price: 27.80
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 0.21 Cr. 2,100,000 Shares
FaceValue 10
About Fabino Life Sciences Ltd.
The company is engaged in manufacturing, marketing, trading and packing of pharmaceutical and other wellness focused consumer products. The company's core business is marketing of pharmaceutical formulation & products in domestic market through own distribution network and sales force under own brand name, getting its ayurvedic formulations manufactured through loan licensing facilities, packing, labeling etc.

Fabino Life Sciences Ltd. Delivery

Delivered Qty
Traded Qty

Fabino Life Sciences Ltd. Performance

1 Day
-3.78%
1 Week
-3.78%
1 Month
-3.78%
3 Month
-10.23%
6 Month
-16.14%
1 Year
-11.57%
2 Year
5 Year
10 Year

Fabino Life Sciences Ltd. Fundamental Ratios

5 years 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 0.02 10.80 3.05 1.74 0.26
Return on Capital Employed (%) 9.44 12.36 2.92 2.48 0.58
Return on Assets (%) 0.00 1.14 1.04 1.37 0.22

Fabino Life Sciences Ltd. Balance Sheet

Particulars 6 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 1 1 1 4 4 4
Non Curr. Liab. 0 1 0 0 0 1
Curr. Liab. 8 2 1 0 0 1
Minority Int.
Equity & Liab. 9 4 2 5 5 5
Non Curr. Assets 1 1 0 0 0 0
Curr. Assets 8 3 2 4 5 5
Misc. Exp. not W/O
Total Assets 9 4 2 5 5 5

Fabino Life Sciences Ltd. Profit and Loss

Particulars 5 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Net Sales 3 8 3 4 3
Other Income 0 0
Total Income 3 8 3 4 3
Total Expenditure -2 -7 -3 -4 -3
PBIDT 0 0 0 0 0
Interest 0 0 0 0 0
Depreciation 0 0 0 0 0
Taxation 0 0 0
Exceptional Items
PAT 0 0 0 0
Adjusted EPS 5 0 0 0

Fabino Life Sciences Ltd. Cash Flow

Particulars 5 years 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 0 2 0 -2 -1
Cash Fr. Inv. 0 0 0 0
Cash Fr. Finan. 0 -2 0 2 0
Net Change 0 0 1 0
Cash & Cash Eqvt 0 0 0 1 0

Fabino Life Sciences Ltd. Shareholding Pattern

4 Qtrs 2022-03 (%) 2022-09 (%) 2023-03 (%) 2023-09 (%)
Promoter 56.82 56.82 56.82 56.82
Public 43.18 43.18 43.18 43.18
Depository Receipts 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00

Fabino Life Sciences Ltd. Announcements

Mon, 13 Nov 2023
Board Meeting Outcome for Outcome Of Board Meeting & Submission Of Unaudited Financial Results For Half Year Ended September 30 2023
In continuation of our letter dated November 02 2023 and November 10 2023 pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Board of Directors the Company at their meeting held today i.e. November 13 2023 at Registered Office of the Company inter alia considered and approved the following;1. The Unaudited Standalone Financial Results set out in compliance with Accounting Standards (AS) for the Quarter and Half Year ended September 30 2023 together with Statement of Assets and Liabilities and Statement of Cash Flow.2. The Unaudited Consolidated Financial Results set out in compliance with Accounting Standards (AS) for the Quarter and Half Year ended September 30 2023 together with Statement of Assets and Liabilities and Statement of Cash Flow.
Mon, 13 Nov 2023
Outcome Of Board Meeting & Submission Of Unaudited Financial Results For Half Year Ended September 30 2023
Outcome of Financial results for the Half-yearly ended September 2023
Fri, 10 Nov 2023
Board Meeting Intimation for Intimation About Adjournment Of Board Meeting Pursuant To Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015
Fabino Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2023 inter alia to consider and approve In continuation of our letter dated November 02 2023 pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 it was intimated that the meeting scheduled to be held on November 10th 2023 now stands adjourned due to non-availability of Directors and the Chairman with the consent of all the directors/members present at the meeting hereby decided to adjourn the Meeting on November 13 2023

Fabino Life Sciences Ltd. Technical Scans

No Scans Found

Fabino Life Sciences Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 295,466.10 1,228.65 -0.2%
Divi's Laboratories Ltd. 100,787.80 3,758.15 -1.0%
Cipla Ltd. 98,218.21 1,219.10 +0.2%
Dr. Reddy's Laboratories Ltd. 95,898.45 5,796.15 +0.7%
Apollo Hospitals Enterprise Ltd. 80,842.20 5,643.05 +0.4%
Mankind Pharma Ltd. 76,792.80 1,941.40 +0.9%
Torrent Pharmaceuticals Ltd. 72,137.95 2,151.80 +0.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-09 34.56 1,228.65 -0.2%
Divi's Laboratories Ltd. Consolidated 2023-09 75.68 3,758.15 -1.0%
Cipla Ltd. Consolidated 2023-09 28.44 1,219.10 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-09 18.84 5,796.15 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-09 115.91 5,643.05 +0.4%
Mankind Pharma Ltd. Consolidated 2023-03 59.91 1,941.40 +0.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-09 54.08 2,151.80 +0.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-09 4.94 1,228.65 -0.2%
Divi's Laboratories Ltd. Consolidated 2023-09 7.95 3,758.15 -1.0%
Cipla Ltd. Consolidated 2023-09 3.96 1,219.10 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-09 3.76 5,796.15 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-09 12.44 5,643.05 +0.4%
Mankind Pharma Ltd. Consolidated 2023-03 9.11 1,941.40 +0.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-09 10.76 2,151.80 +0.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,228.65 -0.2%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,758.15 -1.0%
Cipla Ltd. Consolidated 2023-03 0.02 1,219.10 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 5,796.15 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 5,643.05 +0.4%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 1,941.40 +0.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,151.80 +0.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,228.65 -0.2%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,758.15 -1.0%
Cipla Ltd. Consolidated 2023-03 12.85 1,219.10 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,796.15 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 5,643.05 +0.4%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 1,941.40 +0.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,151.80 +0.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,228.65 -0.2%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,758.15 -1.0%
Cipla Ltd. Consolidated 2023-03 12.85 1,219.10 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,796.15 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 5,643.05 +0.4%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 1,941.40 +0.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,151.80 +0.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,228.65 -0.2%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,758.15 -1.0%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,219.10 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 5,796.15 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 5,643.05 +0.4%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 1,941.40 +0.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,151.80 +0.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,228.65 -0.2%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,758.15 -1.0%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,219.10 +0.2%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 5,796.15 +0.7%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 5,643.05 +0.4%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 1,941.40 +0.9%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,151.80 +0.8%

Fabino Life Sciences Ltd. FAQ's

What is Fabino Life Sciences share price?

Can I buy Fabino Life Sciences shares now?

What is the Market Cap of Fabino Life Sciences?

What are the key metrics to analyse Fabino Life Sciences?

What is the 52 Week High and Low of Fabino Life Sciences?

What is the trend of Fabino Life Sciences share price?